[Hepatitis B immunoglobulin treatment after liver transplantation--our experiences]

L Roznovský1, A Kloudová, L Kabieszová

  • 1Department of Infectious Diseases, University Hospital Ostrava, 17. listopadu 1790, 708 00 Ostrava, Czech Republic. ludek.roznovsky@fnspo.cz

Liver transplantation was performed in 3 patients with hepatitis B infection in 1999-2004 years. Combination of hepatitis B immunoglobulin (HBIg) and lamivudine are used for prevention of hepatitis B recurrence. HBIg is administered in dose 2 000 international units (IU) with tendency to maintain anti-HBs antibodies above 100 IU/litre. Average interval between HBIg administrations was 22, 32 and 32 days, yearly price of treatment was 0.45-0.65 million Czech crowns. Three patients with HBIg and lamivudine therapy are still without recurrence of hepatitis B at the end of 2006 year.